Compare Stocks

→ 3 Sub-$10 Stocks to Buy for 2024 (From TradingTips) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVOK Evoke Pharma	$0.48 -12.8%	$0.62	$0.42 ▼ $2.42	$4.65M	0.22	24,321 shs	20,940 shs
NTEC Intec Pharma		$13.52	$8.80 ▼ $36.88	$8.65M	0.83	543,436 shs	988,300 shs
SAVA Cassava Sciences	$21.19 -0.4%	$21.83	$12.32 ▼ $32.10	$919.84M	-0.45	880,269 shs	966,540 shs
SEEL Seelos Therapeutics	$0.34 +3.0%	$0.77	$0.32 ▼ $49.80	$4.54M	1.88	414,729 shs	272,346 shs

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVOK Evoke Pharma	-12.79%	-11.35%	-21.38%	-37.82%	-77.20%
NTEC Intec Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
SAVA Cassava Sciences	-0.38%	-18.84%	-3.64%	-19.70%	+22.84%
SEEL Seelos Therapeutics	+1.81%	-28.07%	-48.00%	-73.39%	-98.60%

This company has increased its dividend every year for 54 years (Ad)

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	3.4672 of 5 stars	3.5	1.0	0.0	4.7	3.0	0.0	0.6
SEEL Seelos Therapeutics	1.5455 of 5 stars	3.2	4.0	0.0	0.0	0.0	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVOK Evoke Pharma	N/A	N/A	N/A	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	3.00	Buy	$124.00	485.18% Upside
SEEL Seelos Therapeutics	2.33	Hold	$70.00	20,610.06% Upside

Current Analyst Ratings

Latest NTEC, SEEL, SAVA, and EVOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/5/2024	SAVA Cassava Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$124.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVOK Evoke Pharma	$5.18M	0.78	N/A	N/A	($0.77) per share	-0.62
NTEC Intec Pharma	N/A	N/A	N/A	N/A	$16.18 per share	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.26 per share	N/A
SEEL Seelos Therapeutics	$2.20M	2.10	N/A	N/A	($3.42) per share	-0.10

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVOK Evoke Pharma	-$7.79M	-$2.33	N/A	∞	N/A	-150.43%	-517.99%	-91.83%	5/20/2024 (Estimated)
NTEC Intec Pharma	-$14.13M	-$16.32	N/A	N/A	N/A	N/A	-96.37%	-68.87%	N/A
SAVA Cassava Sciences	-$97.22M	-$2.32	N/A	12.69	N/A	N/A	-57.53%	-52.58%	5/6/2024 (Estimated)
SEEL Seelos Therapeutics	-$37.88M	N/A	0.00	∞	N/A	-1,719.56%	N/A	-517.23%	5/20/2024 (Estimated)

Latest NTEC, SEEL, SAVA, and EVOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/14/2024	Q4 2023	EVOK Evoke Pharma	N/A	-$0.59	-$0.59	-$0.59	N/A	$1.68 million
2/28/2024	Q4 2023	SAVA Cassava Sciences	-$0.40	-$0.50	-$0.10	-$0.50	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
NTEC Intec Pharma	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
SEEL Seelos Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVOK Evoke Pharma	N/A	2.25	2.09
NTEC Intec Pharma	N/A	2.34	2.34
SAVA Cassava Sciences	N/A	9.13	9.13
SEEL Seelos Therapeutics	N/A	0.14	0.14

Ownership

Institutional Ownership

Company	Institutional Ownership
EVOK Evoke Pharma	N/A
NTEC Intec Pharma	22.37%
SAVA Cassava Sciences	38.05%
SEEL Seelos Therapeutics	23.37%

Insider Ownership

Company	Insider Ownership
EVOK Evoke Pharma	11.78%
NTEC Intec Pharma	3.30%
SAVA Cassava Sciences	9.00%
SEEL Seelos Therapeutics	5.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EVOK Evoke Pharma	4	8.48 million	7.48 million	Not Optionable
NTEC Intec Pharma	40	898,000	N/A	Optionable
SAVA Cassava Sciences	29	43.25 million	39.35 million	Optionable
SEEL Seelos Therapeutics	15	13.68 million	12.94 million	Optionable

NTEC, SEEL, SAVA, and EVOK Headlines

Source	Headline
	Infusion therapy SLS-005 fails to slow ALS progression in trial alsnewstoday.com - April 4 at 11:49 PM
	SEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023 investorplace.com - March 22 at 3:12 PM
	ALS trial flops but Seelos sees potential for efficacy thepharmaletter.com - March 21 at 6:27 PM
	SLS-005 may slow ALS progression for patients not on Relyvrio: Study alsnewstoday.com - March 20 at 5:39 PM
	Optimistic Buy Rating for Seelos Therapeutics Amid Promising Drug Trial Results markets.businessinsider.com - March 20 at 5:39 PM
	Seelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In Endpoints markets.businessinsider.com - March 19 at 10:34 PM
	Seelos Therapeutics Shares Drop 47% After SLS-005 Trial Misses Primary Endpoints marketwatch.com - March 19 at 10:34 PM
	Nasdaq Down 100 Points; US Housing Starts Surge In February markets.businessinsider.com - March 19 at 5:34 PM
	CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why msn.com - March 19 at 5:34 PM
	Seelos says ALS treatment fails in mid-stage study reuters.com - March 19 at 5:34 PM
	UPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage study finance.yahoo.com - March 19 at 5:34 PM
	Seelos falls as lead drug fails in ALS trial msn.com - March 19 at 9:35 AM
	Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) prnewswire.com - March 19 at 8:15 AM
	From LSD to healing minds: Where are we standing in psychedelic drug development? labiotech.eu - March 13 at 1:26 PM
	Seelos Therapeutics files patent for treatment of neurodegenerative diseases using viral vectors encoding peptides pharmaceutical-technology.com - March 6 at 7:00 PM
	Seelos Therapeutics Inc. thestreet.com - February 9 at 11:53 AM
	Seelos Therapeutics, Inc. (SEEL) ca.finance.yahoo.com - February 1 at 12:51 PM
	Seelos Therapeutics Issues Common Warrants to Investors msn.com - January 31 at 3:52 PM
	Seelos Therapeutics Strikes $4M Direct Offering Deal msn.com - January 31 at 10:18 AM
	Seelos Therapeutics Announces $4 Mln Direct Offering And Private Placement Of Shares markets.businessinsider.com - January 26 at 9:42 PM
	Seelos Therapeutics Shares Hit 52-Week Low After Direct Offering Prices marketwatch.com - January 26 at 9:42 PM
	Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules finance.yahoo.com - January 26 at 9:42 PM
	Seelos Therapeutics Says Received Minutes From End Of Phase II Meeting With FDA markets.businessinsider.com - January 22 at 10:13 AM
	Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002 finance.yahoo.com - January 22 at 10:13 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Evoke Pharma

NASDAQ:EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Intec Pharma

NASDAQ:NTEC

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

Cassava Sciences

NASDAQ:SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Seelos Therapeutics

NASDAQ:SEEL

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial